ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
35.38
-0.92%
US Tech 100
18,092.43
-0.75%
S&P 500
5,264.00
-0.81%
US Dollar vs CAD
1.37398
0.35%
Bitcoin
67,264.24
-2.66%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. ImmunityBio Inc (IBRX)

  7. ImmunityBio Inc (IBRX) News

IBRX

ImmunityBio (IBRX)

ImmunityBio Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:IBRX
DateTimeSourceHeadlineSymbolCompany
05/17/20248:00AMBusiness WireConnecting the Dots of ANKTIVA’s Triangle Offense: A Deep Dive with Dr. Patrick Soon-Shiong and Dr. Ashish Kamat in a Three-Part UroToday PodcastNASDAQ:IBRXImmunityBio Inc
05/09/20244:00PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:IBRXImmunityBio Inc
05/07/20247:00AMBusiness WireImmunityBio Completes GMP Drug Substance Manufacturing Sufficient for 170,000 Doses of ANKTIVA®NASDAQ:IBRXImmunityBio Inc
05/02/20243:04PMBusiness WireImmunityBio, Serum Institute of India Agree on an Exclusive Arrangement for Global Supply of Bacillus Calmette-Guerin (BCG) Across All Cancer TypesNASDAQ:IBRXImmunityBio Inc
04/30/20247:00AMBusiness WireImmunityBio Executive Chairman Dr. Patrick Soon-Shiong to Discuss ANKTIVA® Approval in Fireside Chat at the Annual Conference of the American Urological AssociationNASDAQ:IBRXImmunityBio Inc
04/24/202411:03PMBusiness WireImmunityBio Announces Positive Overall Survival Results of Anktiva Combined With Checkpoint Inhibitors in Non-Small Cell Lung Cancer; Meeting Scheduled with FDA to Discuss Registration Path for ANKTIVA in Lung CancerNASDAQ:IBRXImmunityBio Inc
04/22/20248:56PMBusiness WireImmunityBio Announces FDA Approval of ANKTIVA®, First-in-Class IL-15 Receptor Agonist for BCG-Unresponsive Non-Muscle Invasive Bladder CancerNASDAQ:IBRXImmunityBio Inc
03/06/20248:00AMBusiness WireNIAID-Sponsored Study Shows N-803 Combined with Neutralizing Antibodies Could Lead to Sustained HIV Viral Control After Discontinuation of Antiretroviral TherapyNASDAQ:IBRXImmunityBio Inc
03/05/20248:00AMBusiness WireN-803 Combined with Natural Killer Cells Showed Potential to Reduce HIV Viral Load in HIV Positive Subjects; Part of HIV Cure StudyNASDAQ:IBRXImmunityBio Inc
02/26/20243:43PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IBRXImmunityBio Inc
02/26/20243:40PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IBRXImmunityBio Inc
02/26/20243:38PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IBRXImmunityBio Inc
02/23/20248:28PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:IBRXImmunityBio Inc
02/21/20248:00AMBusiness WireImmunityBio Announces Full Accrual of First Two Phases of Cancer Vaccine Trial in Participants with Lynch Syndrome and Initiation of Randomized Controlled Phase of the TrialNASDAQ:IBRXImmunityBio Inc
02/06/20248:14PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IBRXImmunityBio Inc
02/05/20248:00AMBusiness WireImmunityBio Quality-of-Life Study in BCG-Unresponsive Bladder Cancer Trial Indicates Improved Physical Function in the 71% Complete Responders Suggesting a Favorable Risk-Benefit Ratio for N-803 Plus BCGNASDAQ:IBRXImmunityBio Inc
02/02/20246:38PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IBRXImmunityBio Inc
02/02/20246:33PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IBRXImmunityBio Inc
01/03/20248:59PMEdgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:IBRXImmunityBio Inc
01/03/20248:41PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IBRXImmunityBio Inc
01/03/20248:40PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IBRXImmunityBio Inc
01/02/20245:08AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:IBRXImmunityBio Inc
01/02/20245:00AMBusiness WireImmunityBio Announces $320 Million Investment by Oberland Capital, with $210 Million Funded at Closing, Bringing Total Financing in 2023 to $850 MillionNASDAQ:IBRXImmunityBio Inc
11/16/20238:00AMBusiness WireImmunityBio to Participate in 35th Annual Piper Sandler Healthcare ConferenceNASDAQ:IBRXImmunityBio Inc
11/08/20238:28PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:IBRXImmunityBio Inc
11/07/20238:00AMBusiness WireFirst Data for ImmunityBio’s Memory Cytokine-Enriched NK Cells in Small Cell Lung Cancer at SITC Meeting Show Promising Anti-tumor ActivityNASDAQ:IBRXImmunityBio Inc
10/26/202311:03AMDow Jones NewsImmunityBio Shares Rally as FDA Accepts N-803 ResubmissionNASDAQ:IBRXImmunityBio Inc
10/26/20238:00AMBusiness WireFDA Accepts ImmunityBio’s BLA Resubmission as Complete and Sets New PDUFA DateNASDAQ:IBRXImmunityBio Inc
10/23/202310:00AMDow Jones NewsImmunityBio Shares 11% Higher on License Application Resubmission for N-803NASDAQ:IBRXImmunityBio Inc
10/23/20238:00AMBusiness WireImmunityBio Announces Biological License Application Resubmission for N-803 in BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer Carcinoma-In-SituNASDAQ:IBRXImmunityBio Inc
 Showing the most relevant articles for your search:NASDAQ:IBRX

Your Recent History

LSE
QU87
Mor.st.fin 27
DBI
I1LD
INAV XT2 GEGOBHEL
BIT
P1THX8
NLBNPIT1THX8 20240621 220
Delayed Upgrade Clock
ADVFN Logo

Canada
Company
Business
Popular
Get The App

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved